baber/WOPTO huggingface dataset:
Patent NZ-526427-A (NZ)
Title: Diagnostic assay to determine the presence or absence of a particular mutation or polymorphism in a target nucleotide sequence
Inventor: SIEMERING KIRBY
IPC: C12Q1/68
Filed: 2001-12-20
Abstract: A method for determining the presence or absence of a homozygous or heterozygous change in one or more nucleotides within a target nucleotide sequence is described. The method combines hybridisation of two differently labelled probes A and B on either side of a restriction site, restriction endonuclease digestion, and detection of the labels in the resulting digest using forward and reverse primers to produce an amplified product, wherein at least one of the primers is labelled with a reporter molecule capable of facilitating the provision of an identifiable signal which can be distinguished from another reporter molecule if both primers are labelled and wherein at least one primer and its complementary form comprises a complementary sequence to an oligonucleotide sequence anchored to a solid support and wherein one or more of said forward or reverse primers introduces or abolishes a target site within the amplified product in the presence or absence of a change in one or more nucleotides, and subjecting said amplified product to detection means. If an organism is: homozygous then the labels will be present in the ratio 1:1 or 1:0; or if heterozygous then the labels will be present in the ratio 1:2. Either immobilised array technology or electrophoretic separation may be used as detection means.
Patent NZ-526800-A (NZ)
Title: Formula for preparation of complex fungal polysaccharides
Inventor: GAO YI HUAI
IPC: A61K31/715
Filed: 2003-11-07
Abstract: An active fungal polysaccharide preparation is disclosed, which comprises a water soluble polysaccharide obtained from a fungus such as Ganodermal Lucidum and an acid soluble polysaccharide obtained from the same or a different fungus, wherein the water soluble polysaccharide is neutral and the acid soluble polysaccharide is alkaline. This active fungal polysaccharide preparation is suitable for providing beneficial effect in the treatment of cancerous tumor cells.
Patent NZ-529623-A (NZ)
Title: Pharmaceutical formulation for intraduodenal administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof
Inventor: WIKSTROM HAKAN
IPC: A61K9/16
Filed: 2002-06-07
Abstract: Disclosed is a pharmaceutical formulation for the treatment of an affliction selected from the group consisting of Parkinson's disease, restless legs syndrome and erectile dysfunction, which composition comprises at least one member selected from the group consisting of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof in the form of the base or the pharmaceutically acceptable salts or solvates thereof as an active ingredient in a pharmaceutical preparation in either the form of an oral formulation having an enteric coating that dissolves in the small intestine or a form suited for administration intraduodenally by intraduodenal catheter through the abdominal wall of a patient or by naso-duodenal catheter, wherein said "derivative" or "pro-drug" is a compound of the formula (I), wherein: R1 and R2 are hydrogen, or one of R1 and R2 is hydrogen or acetyl and the other one is selected from the group consisting of (C2-C20) alkanoyl; halo-(C3-C20) alkanoyl; (C3-C20) alkenoyl; (C4-C7) cycloalkanoyl; (C3-C6)-cycloalkyl(C2-C16)alkanoyl; aroyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (C1-C3) alkyl and (C1-C3) alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; aryl (C2-C16) alkanoyl which is unsubstituted or substituted in the aryl moiety by 1 to 3 substituents selected from the group consisting of halogen, (C1-C3) alkyl and (C1-C3) alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; and hetero-arylalkanoyl having one to three heteroatoms selected from O, S and N in the heteroaryl moiety and 2 to 10 carbon atoms in the alkanoyl moiety and which is unsubstituted or substituted in the heteroaryl moiety by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethane-sulphonyloxy, (C1-C3) alkyl, and (C1-C3) alkoxy, which latter may be in turn be substituted by 1 to 3 halogen atoms; and R3 is selected from the group consisting of methyl and propyl.
Patent NZ-530160-A (NZ)
Title: Golf tee positioner
Inventor: MOTION TERRENCE ANTONY COLIN
IPC: A63B57/00
Filed: 2003-12-15
Abstract: An apparatus for releasably retaining and positioning a golf tee, the apparatus including at least: a body with one or more tee head abutment surfaces lying in a first plane, the abutment surface or surfaces forming a contact portion for engaging the head of the golf tee; and at least one limb; the or each limb being attached to, or integrally formed with, the body; the or each limb having a respective distal end which is located outwardly of the contact portion and is moveable relative to the contact portion to vary the distance between the respective distal end and the first plane.
Patent NZ-535603-A (NZ)
Title: Substituted phenylacetic acids
Inventor: ZHAO ZUCHUN
IPC: C07D277/66
Filed: 2003-03-19
Abstract: Disclosed are substituted phenylacetic acid compounds of formula Ia and Ib wherein X is a member selected from O, S, SO and SO2 and all other substituents are as described in the specification. These compounds are utilised in treating a number of diseases associated with glucose metabolism, lipid metabolism and insulin secretion.
Patent NZ-539670-A (NZ)
Title: Pyrimidine compounds
Inventor: WANG SHUDONG
IPC: C07D417/04
Filed: 2003-11-14
Abstract: Disclosed are substituted pyrimidines of formula (Ib), their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.
Patent NZ-542293-A (NZ)
Title: Aqueous dispersion for internal sizing or surface sizing in the production of paper
Inventor: KRUCKEL RALF
IPC: D21H17/09
Filed: 2004-03-04
Abstract: An aqueous dispersion useful for internal sizing or surface sizing in the production of paper is disclosed, which comprises at least one cellulose reactive sizing agent selected from the group consisting of ketene dimers and multimers, at least one cellulose non-reactive sizing agent and at least one emulsifier selected from the group consisting of oxyalkylene phosphate esters and salts thereof and oxyalkylene sulfate esters and salts thereof. The disclosure further relates to a process for its preparation, use thereof, and processes for the production of paper.
Patent NZ-544296-A (NZ)
Title: A juicer lid with a feed tube made from steel
Inventor: HENSEL KEITH JAMES
IPC: A47J43/07
Filed: 2004-06-24
Abstract: A lid (12) for an electric juicing device is disclosed. The lid (12) comprises a polymeric cap (52) in which is formed an opening the opening accommodating and having attached to it a metal feed tube (51) which is stronger than the usual polymer feed tubes.
Patent NZ-545030-A (NZ)
Title: 2-(Quinoxalin-5-ylsulfonylamino) -benzamide compounds as CCK2 modulators
Inventor: ALLISON BRETT D
IPC: A61P1/18
Filed: 2004-08-04
Abstract: Disclosed are amidophenyl-sulfonylaminoquinoxaline compounds of formula (I), processes for their preparation and intermediates for use therein, including quinoxaline-5-sulfonyl chlorides of formula D1. The compounds are CCK2 modulators useful in the treatment of diseases such as pancreatic adenocarcinoma, pain, gastro-esophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors and gastric tumors.
Patent NZ-547375-A (NZ)
Title: Use of rimonabant and an angiotensin II AT1 receptor antagonist for preparing medicaments for the prevention and the treatment of dyslipidemia and/or obesity
Inventor: ARNONE MICHELE
IPC: A61P9/00
Filed: 2004-10-22
Abstract: Disclosed is the use of rimonabant for the manufacture of a medicament for the treatment or prevention of a disease related to dyslipidemia and/or obesity, wherein the disease is metabolic syndrome or liver steatosis, in which the medicament further comprises an angiotensin II AT1 receptor antagonist. Further disclosed is a medicament comprising rimonabant and an angiotensin II AT1 receptor antagonist, and optionally a diuretic or a calcium antagonist.
Patent NZ-551013-A (NZ)
Title: Composition comprising 0-29% cis-clomiphene and 79-100% trans-clomiphene testosterone deficiency in men
Inventor: PODOLSKI JOSEPH S
IPC: A61K31/138
Filed: 2002-07-09
Abstract: Disclosed is a composition comprising 0-29% cis-clomiphene and 79-100% trans-clomiphene or analogues, pharmaceutically acceptable salts and pharmaceutically acceptable dilatants, adjuvuncts or excipients. (62) Divided Out of 530491
Patent NZ-555346-A (NZ)
Title: Security element having a viewing-angle dependent aspect
Inventor: SCHMID MATHIEU
Filed: 2005-11-10
Abstract: Security element for a document of value, right, identity, for a security label or a branded good, comprising a substrate 1, which contains indicia or other visible features 2 in or on its surface, and on at least part of the substrate surface, a coating layer comprising pigment flakes 3 in a cured, transparent binder, wherein the pigment flakes 3 in the coating layer are absorbing in at least part of the visible spectrum, and are locally oriented such as to give visibility to the underlying indicia or other visible features 2 along at least one specific direction of observation and to impede visibility to the underlying indicia or other visible features 2 along at least another direction of observation, and wherein the orientation of the pigment flakes 3 in the cured, transparent binder does not itself comprise or reflect the indicia or other visible features 2 which are present in or on the surface of the substrate.
Patent NZ-556654-A (NZ)
Title: Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
Inventor: ALBERS RONALD
IPC: C07D473/00
Filed: 2006-01-13
Abstract: Disclosed is a compound having the formula (I) wherein the substituents are described in the specification. Also disclosed is the use of the compound in a preparation for treating or preventing a metabolic disease, cancer, a cardiovascular disease, a renal disease, an autoimmune disease, macular degeneration, ischemia-reperfusion injury, pain or a pain-related syndrome, disease-related wasting, an asbestos-related condition, central nervous system injury/damage or pulmonary hypertension.
Patent NZ-561169-A (NZ)
Title: Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
Inventor: BACHMANN BRIAN O
IPC: C12N9/90
Filed: 2004-01-21
Abstract: Disclosed is a farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present disclosure further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the disclosure relates to polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.
Patent NZ-561906-A (NZ)
Title: Segmented duct for fibre optic cables
Inventor: REISS GERHARD
IPC: H02G3/04
Filed: 2005-05-25
Abstract: A cable duct for cables, which are to be laid along walls or tops of subterranean tubes or ducts for the transport of water or sewage or similar, for energy data and information transfer, in particular, for optical fibre cables, whereby the cable duct may be installed in the tube from the surface through access shafts and fixed to the duct wall or top. The cable duct is characterised in being formed by similar, longitudinal cable duct body elements (10), arranged one behind the other in the longitudinal direction (rl), connected to each other at the ends thereof such as to be pivoted relative to each other at a lateral angle about a lateral pivot axis (as), each being formed by two cover plates (2, 2'), connected and held parallel to each other by a web (3), arranged in the middle. The laterally open chambers (20, 20'), arranged to both sides of the web, between the cover plates, provided for the subsequent housing of the cables (6), may be sealed to both sides by edge cover strips (51) with interlocking elements (52) along the longitudinal edges thereof which interlock with corresponding counter interlocking elements (22) on the longitudinal edges of the cover plates of the body elements which are made from an elastically flexible material, to form two closed longitudinal chambers (200, 200'), from the connected angularly adjustable body elements, separated from each other by the webs of each of the body elements, through which the cable duct may be passed.
Patent NZ-563577-A (NZ)
Title: Imidazolone phenylalanine derivatives as VLA-4 antagonists
Inventor: STAPPENBECK FRANK
IPC: A61K31/437
Filed: 2006-05-22
Abstract: Disclosed are imidazolone phenylalanine derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof, wherein A is H, optionally substituted aryl, optionally substituted heteroaryl or -C(X)D(R3)Z and Q is an aryl or heteroaryl substituted imidazolone. Also disclosed is the use of the above mentioned compounds for the preparation of a medicament for treating a disease state caused or exacerbated at least in part by alpha 4 integrin-mediated leukocyte binding in a patient. Such diseases encompassed within the scope of the invention include autoimmune disease, multiple sclerosis, meningitis, encephalitis, stroke, asthma, adult respiratory distress syndrome, acute leukocyte-mediated lung injury, rheumatoid arthritis and the like.
Patent NZ-568250-A (NZ)
Title: A method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
Inventor: YAN WEN LIANG
IPC: C12N5/073
Filed: 2002-01-02
Abstract: Disclosed is an in vitro method for producing a depository of genotyped mammalian homozygous embryonic stem (HES) cells, wherein each HES cell that produces a cell line has alleles that are homozygous for one or more genes of interest, comprising; (a) selecting mammalian donors; (b) determining the genotype of each donor, wherein determining the genotype comprises determining whether each of the one or more genes of interest (i) has a sequence not known to be associated with any pathological condition or (ii) contains one or more genetic mutations known to be associated with a pathological condition; (c) mitotically activating non-fertilized post-meiosis I diploid oocytes obtained from each donor to develop multiple blastocyst-like masses, each of which contains an inner cell mass (ICM) that is homozygous for each of the one or more genes of interest, wherein the non-fertilized post-meiosis I diploid oocytes are incubated with calcium ionophore and are incubated with 6-dimethylaminopurine; (d) isolating I-LES cells from the ICM obtained from each donor; (e) culturing the isolated HES cells to obtain HES cell lines; (f) determining the genotype of each HES cell line, wherein determining the genotype comprises determining whether each of the one or more genes of interest (i) has a sequence not known to be associated with any pathological condition or (ii) contains one or more genetic mutations known to be associated with a pathological condition; and (g) cataloging the genotype of each HES cell line obtained in (e), with the proviso that the HES cell produces a cell line that does not include alleles that are homozygous for a Major Histocompatibility Complex (MHC) haplotype.
Patent NZ-580344-A (NZ)
Title: Process for making topotecan
Inventor: HU TSUNG-CHENG
IPC: C07D491/22
Filed: 2008-04-10
Abstract: Disclosed herein is a process for preparing topotecan or a pharmaceutically acceptable slat thereof, comprising reacting 10-hydroxy-camptothecin with an iminium salt of formula (I): [H2C=NR1R2]+ X (I) Wherein R1 and R2 represent a methyl group or a CH2R3 group, R3 represents a protective group; X represents an anion; in the presence of a base and an organic solvent.
Patent NZ-584908-A (NZ)
Title: Turbine assembly with plural blades of different diameter in reversed orientation
Inventor: WEST STEPHEN MARK
IPC: E02B9/00
Filed: 2008-10-06
Abstract: A turbine unit (11) comprising a passage (23) through which a fluid may pass. Located within the passage (23) is a driving turbine blade set (25) upstream from a pumping turbine blade set (27) wherein the diameter of the pumping turbine blade is larger than the diameter of the driving turbine blade set. The driving turbine blade set and pumping turbine blade set are mounted in opposed relation whereby the turbine blade sets are in reversed orientation with respect to each other such that in simultaneous operation a region between the two turbine blade sets has a lower pressure than the fluid pressure at an opening of the passage. This induces a greater mass flow rate through the turbine unit than would otherwise be created by a pumping turbine blade set equal to or smaller in diameter than the driving turbine blade set.
Patent NZ-586918-A (NZ)
Title: Personal protection apparatus for the prevention of injury from rock falls in underground mining operations
Inventor: ROCHFORD KELLY ROSS
IPC: A41D13/05
Filed: 2010-07-20
Abstract: Personal protection apparatus for the prevention of injury from rock falls in underground mining operations is disclosed. The personal protection apparatus includes a plurality of armour pads, spacing, and fastening means. The plurality of armour pads protect one or more regions of the body of a user. The spacing means are operatively associated with the one or more armour pads and space the armour pads, substantially in their entirety, from the body of the user, and the fastening means releasably fasten the one or more armour pads to the body of the user. The plurality of armour pads include one or more spinal pads for protecting a spinal region and forming a spine protector, and the remaining the armour pads are attached to the spine protector at spaced intervals there-along so as to locate the armour pads over the appropriate areas of the body for protection.
Patent NZ-590064-A (NZ)
Title: Cancer diagnosis based on levels of antibodies against globo h and its fragments
Inventor: WONG CHI-HUEY
IPC: G01N33/574
Filed: 2009-06-16
Abstract: A cancer diagnostic method that comprises the steps: (a) Providing a sample containing antibodies from a subject suspected of having cancer; (b) Incubating the sample with Gb5 and one or more of Globo H, Bb2, Bb3 and Bb4 to allow binding of the antibodies in the sample to the Gb5 and the Globo H, Bb2, Bb3 and Bb4; (c) Measuring the amount of the GB-5-bound antibodies and the amount of the Globo H-bound, Bb2-bound, Bb3-bound and Bb4-bound antibodies; (d) Determining whether the subject has the cancer based on the amounts of Gb5-bound antibodies and the Globo H-bound, Bb2-bound, Bb3-bound and Bb4-bound antibodies; The cancer is Globo H-positive and GB5-positive; and a higher ratio of the amount of Globo H-bound, Bb2-bound, Bb3-bound and Bb4-bound antibodies to the amount of Gb5-bound antibodies compared to a cancer-free subject indicates the subject has cancer. The cancer can be breast cancer, skin cancer, liver cancer, prostate cancer, ovary cancer, colon cancer, stomach cancer or pancreas cancer.
Patent NZ-592289-A (NZ)
Title: Anti-Angiogenic Agents and Methods of Use
Inventor: ZHICAN QU
IPC: A01N43/54
Filed: 2008-04-14
Abstract: Disclosed herein is the use of clomipramine in the manufacture of a medicament for inhibiting the growth or metastasis of a human breast or ovarian tumor by reducing or preventing angiogenesis in a human in need thereof. Also disclosed is the use of clomipramine in the manufacture of a medicament for treating a disease or disorder associated with angiogenesis in a human in need thereof, wherein the disease or disorder is selected from the group consisting of restenosis, rheumatoid arthritis, Crohn's disease, diabetic retinopathy, psoriasis, endometriosis, macular degeneration, neovascular glaucoma, and adiposity.
Patent NZ-592703-A (NZ)
Title: A hinge having a hydraulic damper and a latch and return to closed function
Inventor: BACCHETTI LUCIANO
IPC: E05D7/08
Filed: 2010-08-04
Abstract: A hinge for cold room doors, swing gates or the like is disclosed. The hinge comprises a box-like hinge body (3) and a pin (5) reciprocally rotatably coupled to rotate about a first axis (X) between the open door position and the closed door position. Closing means are provided (10) for automatically returning the door, as well as a working fluid to slow the automatic return. The closing means comprise a cam element (11) unitary with the pin interacting with a plunger element (12) housed in an operating chamber (25) defined within the box-like hinge body. The box-like hinge body has an elongated shape to define a second axis (Y) perpendicular to the first one (X). The plunger element has a substantially cylindrical back portion and a front portion defining a pushing head, the back portion being designed to separate the operating chamber into a first and a second variable volume compartments, in reciprocal fluid communication with each other. The operating chamber also has a control means (26) for controlling the flow of the working fluid between the first and second variable volume compartments. This flow control means having a tubular element (55 Fig 6) interposed between the inner surface of the operating chamber and the back portion of the plunger element to define at least one first hydraulic circuit for the working fluid. The plunger element is tightly housed in the tubular element; the tubular element being tightly housed in the operating chamber.